MX2019003544A - Compositions comprising a cannabinoid receptor binding ligand. - Google Patents

Compositions comprising a cannabinoid receptor binding ligand.

Info

Publication number
MX2019003544A
MX2019003544A MX2019003544A MX2019003544A MX2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding ligand
cannabinoid receptor
compositions
medicament
Prior art date
Application number
MX2019003544A
Other languages
Spanish (es)
Inventor
Günther Bernhard
Löscher Frank
Krösser Sonja
Steven Philipp
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019003544A publication Critical patent/MX2019003544A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

The present invention provides a pharmaceutical composition comprising: a) a therapeutically effective amount of at least one cannabinoid receptor binding ligand, and b) a liquid vehicle comprising at least one semifluorinated alkane; as well as the use of such pharmaceutical compositions as a medicament.
MX2019003544A 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand. MX2019003544A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
MX2019003544A true MX2019003544A (en) 2019-09-19

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003544A MX2019003544A (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand.

Country Status (10)

Country Link
US (1) US20190343793A1 (en)
EP (2) EP3698785A1 (en)
JP (1) JP2019534867A (en)
KR (1) KR20190060787A (en)
CN (1) CN109803650A (en)
AU (1) AU2017333420A1 (en)
BR (1) BR112019006194A2 (en)
CA (1) CA3036313A1 (en)
MX (1) MX2019003544A (en)
WO (1) WO2018060282A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869345B (en) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DK3181119T3 (en) 2012-09-12 2019-09-16 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS TO USE IN TREATMENT OF KERATOCONJUNCTIVITIS SICCA
CN113662928A (en) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 Semi-fluorinated compounds for ophthalmic administration
JP6602964B2 (en) 2015-09-30 2019-11-06 ノバリック ゲーエムベーハー Semifluorinated compounds and compositions thereof
MX2019003363A (en) 2016-09-22 2019-10-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis.
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
BR112019021917A8 (en) 2017-04-21 2023-03-21 Novaliq Gmbh IODINE COMPOSITIONS
CN110650734A (en) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of conditions associated with contact lenses
CN111372566A (en) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 Ophthalmic composition comprising latanoprost for treating ocular diseases
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh Ophthalmic compositions comprising f6h8
CN111526914A (en) 2017-10-04 2020-08-11 精呼吸股份有限公司 Electronic respiration actuated linear liquid drop conveying device and using method thereof
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP2022523332A (en) * 2019-02-01 2022-04-22 アエリエ ファーマシューティカルズ インコーポレイテッド Compounds, Compositions and Methods for Treating Myopia
IL301902A (en) * 2020-10-05 2023-06-01 Max Biology Co Ltd Cannabinoid-containing compositions and use for treating and preventing diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
US11793945B2 (en) 2021-06-22 2023-10-24 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
WO2023064477A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (en) * 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
AU2009308665B2 (en) 2008-10-31 2015-10-22 The University Of Mississippi Compositions containing delta-9-THC-amino acid esters and process of preparation
AT509000B1 (en) * 2009-10-23 2012-12-15 Rausch Peter WATER-SOLUBLE PREPARATIONS OF CANNABINOIDS AND CANNABIC PREPARATIONS AND THEIR APPLICATIONS
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
AU2013314370B2 (en) * 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
DK3181119T3 (en) * 2012-09-12 2019-09-16 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS TO USE IN TREATMENT OF KERATOCONJUNCTIVITIS SICCA
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MA41299A (en) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc OPHTHALMIC SOLUTIONS FOR THE TREATMENT OF GLAUCOMA AND CONJUNCTIVITIS

Also Published As

Publication number Publication date
WO2018060282A1 (en) 2018-04-05
CA3036313A1 (en) 2018-04-05
US20190343793A1 (en) 2019-11-14
AU2017333420A1 (en) 2019-04-04
JP2019534867A (en) 2019-12-05
EP3698785A1 (en) 2020-08-26
BR112019006194A2 (en) 2019-06-18
KR20190060787A (en) 2019-06-03
CN109803650A (en) 2019-05-24
EP3518921B1 (en) 2021-08-11
EP3518921A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
MX2019003544A (en) Compositions comprising a cannabinoid receptor binding ligand.
MX2022010168A (en) Calpain modulators and therapeutic uses thereof.
MX2018006217A (en) Apelin receptor agonists and methods of use.
MX2018005340A (en) Proteolysis targeting chimera compounds and methods of preparing and using same.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MY195244A (en) Muscarinic Agonists
MX2016014515A (en) Topical gel cream composition.
MX2015016171A (en) Azetidine estrogen receptor modulators and uses thereof.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2015011132A (en) Polycyclic estrogen receptor modulators and uses thereof.
BR112016018062A8 (en) therapeutic compounds, pharmaceutical composition and uses
EP3957723A3 (en) Engineered ligase variants
PH12019502692A1 (en) Anti-cancer combination therapy
MX2019001121A (en) New cannabis tablet formulations and compositions and methods of making the same.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2017008390A (en) Alkoxysilane-functionalized and allophanate-functionalized urethanes.
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
MX2018015125A (en) New antibacterial compounds.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
IL276888A (en) Pharmaceutical composition comprising timolol
AU2018279184A1 (en) Anti-TrkB antibodies
MX2019007574A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.
IL277649A (en) Anticancer pharmaceutical compositions for combined therapy
EP3875091A4 (en) Pharmaceutical composition containing antitumor agent